health-issue
Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
https://ift.tt/5CyKS1v Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS from Sanofi - Aventis Gr…
Read more
health-issue
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
https://ift.tt/0rdakEh Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM from Sano…
Read more
health-issue
Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy
https://ift.tt/GJmyQcW Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammator…
Read more
health-issue
Press Release: Availability of the Q2 2024 Aide-mémoire
https://ift.tt/uiPfq5W Availability of the Q2 2024 Aide-mémoire from Sanofi - Aventis Groupe https://ift.tt/XoIW75n via IFTTT
Read more
health-issue
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
https://ift.tt/RHUqpgJ Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee from Sanofi - Aven…
Read more
health-issue
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
https://ift.tt/h5VgO4Q ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran from Sanofi - Aventis Groupe https…
Read more
health-issue
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
https://ift.tt/Fq7D06Y Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa from Sanofi - Aventis Groupe https://ift.tt/…
Read more
health-issue
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
https://ift.tt/NytGSV9 ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnos…
Read more
